MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE

Real-time Quotes | Nasdaq Last Sale

107.98
+0.14
+0.13%
After Hours: 107.98 0 0.00% 16:00 05/24 EDT
OPEN
108.49
PREV CLOSE
107.84
HIGH
108.98
LOW
107.29
VOLUME
866.68K
TURNOVER
0
52 WEEK HIGH
122.16
52 WEEK LOW
78.71
MARKET CAP
187.78B
P/E (TTM)
33.83
1D
5D
1M
3M
1Y
5Y
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 23 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation...
GlobeNewswire · 1d ago
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Zacks · 4d ago
4 Large Drug Stocks to Watch as the Industry Recovers
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Zacks · 5d ago
Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.
Investor's Business Daily · 05/16 17:16
Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation...
GlobeNewswire · 05/16 14:04
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
Zacks · 05/16 13:28
Eli Lilly's dual-receptor diabetes drug tirzepatide granted FDA approval
The U.S. FDA has approved Eli Lilly's (NYSE:LLY) Mounjaro (tirzepatide), the first-ever diabetes medication that activates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Mounjaro is given once a
Seekingalpha · 05/13 19:44
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Benzinga · 05/13 16:26
More
No Data
Learn about the latest financial forecast of NVO. Analyze the recent business situations of Novo-Nordisk A/S through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NVO stock price target is 129.39 with a high estimate of 135.85 and a low estimate of 121.11.
High135.85
Average129.39
Low121.11
Current 107.98
EPS
Actual
Estimate
0.230.470.700.93
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.13K
Institutional Holdings: 151.34M
% Owned: 8.70%
Shares Outstanding: 1.74B
TypeInstitutionsShares
Increased
278
11.92M
New
78
3.31M
Decreased
290
8.29M
Sold Out
57
793.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Helge Lund
President/Chief Executive Officer
Lars Fruergaard Joergensen
Vice Chairman/Director
Jeppe Christiansen
Chief Financial Officer/Executive Vice President
Karsten Munk Knudsen
Chief Operating Officer/Executive Vice President
Maziar Doustdar
Executive Vice President/Chief Scientific Officer
Marcus Schindler
Executive Vice President/Director of Human Resources
Monique Carter
Executive Vice President
Ludovic Helfgott
Executive Vice President
Douglas Langa
Executive Vice President
Martin Lange
Executive Vice President
Camilla Sylvest
Executive Vice President
Henrik Wulff
Director
Mette Boejer Jensen
Director
Kasim Kutay
Director
Anne Kverneland
Director
Henrik Poulsen
Director
Thomas Rantzau
Director
Stig Stroebaek
Independent Director
Laurence Debroux
Independent Director
Andreas Fibig
Independent Director
Sylvie Gregoire
Independent Director
Martin Mackay
No Data
No Data
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.